Transition Therapeutics (TTHI) 8.08 $TTHI
Transition Therapeutics Up 43.1% Since SmarTrend Uptrend Call (TTHI)
Comtex SmarTrend(R) - Tue Apr 21, 9:49AM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 11 months, Transition Therapeutics has returned 43.09% as of today's recent price of $7.92.
TTHI: 8.08 (+0.08)
BUYINS.NET: SMCI, PPO, TTHI, HCKT, NEPT, HST Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Apr 15, 6:24AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Super Micro Computer Inc (NASDAQ:SMCI), Polypore International Inc (NYSE
PO), TRANSITION THERAPEUTICS INC (NASDAQ:TTHI), HACKETT GROUP INCORPORATION.(THE) (NASDAQ:HCKT), Neptun SA (NASDAQ:NEPT), Host Hotels and Resorts Inc (NYSE:HST) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
HST: 20.62 (+0.07), SMCI: 31.90 (-2.91), PPO: 58.63 (+0.12), TTHI: 8.08 (+0.08), NEPT: 1.77 (-0.01), HCKT: 9.96 (+0.02)
Transition Therapeutics Has Returned 27.4% Since SmarTrend Recommendation (TTHI)
Comtex SmarTrend(R) - Tue Apr 14, 9:23AM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 10 months, Transition Therapeutics has returned 27.37% as of today's recent price of $7.05.
TTHI: 8.08 (+0.08)
Shares of TTHI Up 23.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 06, 5:26PM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 10 months, Transition Therapeutics has returned 23.39% as of today's recent price of $6.83.
TTHI: 8.08 (+0.08)
Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of Neuropsychiatric Drug Candidate ELND005
PR Newswire - Thu Mar 26, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX:TTH) today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME" study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration ("FDA" for the approval of most drugs in development.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
Uptrend Call Working As Transition Therapeutics Stock Rises 27.2% (TTHI)
Comtex SmarTrend(R) - Fri Mar 20, 5:00PM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 9 months, Transition Therapeutics has returned 27.19% as of today's recent price of $7.04.
TTHI: 8.08 (+0.08)
Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in Agitation and Aggression in Patients with Alzheimer's Disease
PR Newswire - Mon Mar 02, 5:02AM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited ("TTIL" completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD".
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
Transition Therapeutics concludes public offering of common stock
M2 - Thu Feb 19, 4:04AM CST
Biopharmaceutical company Transition Therapeutics (NASDAQ:TTHI)(TSX:TTH) disclosed on Wednesday the completion of its public offering of 3,538,461 common shares at USD6.50 per share.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares
PR Newswire - Wed Feb 18, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) today announced the closing of its underwritten public offering of an aggregate of 3,538,461 common shares at a price to the public of US$6.50 per share, including 461,538 common shares issued upon the exercise of the underwriters' over-allotment option. Cowen and Company, LLC was the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC were the co-managers for the offering.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
22.3% Return Seen to Date on SmarTrend Transition Therapeutics Call (TTHI)
Comtex SmarTrend(R) - Thu Feb 12, 11:04AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 8 months, Transition Therapeutics has returned 22.31% as of today's recent price of $6.77.
TTHI: 8.08 (+0.08)
Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares
PR Newswire - Thu Feb 12, 7:00AM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) today announced the pricing of its underwritten public offering of 3,076,923 common shares at a price to the public of US$6.50 per share for total gross proceeds of US$20 million. The Company has granted the underwriters a 30-day option to purchase up to an additional 461,538 common shares, which could result in an additional US$3 million of gross proceeds. The offering is expected to close on February 18, 2015, subject to customary closing conditions. Cowen and Company, LLC is the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC are the co-managers for the offering.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
Transition Therapeutics initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:20PM CST
TTHI: 8.08 (+0.08)
Transition Therapeutics Inc. Announces Public Offering of Common Shares
PR Newswire - Wed Feb 11, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) announced today that it has commenced an underwritten public offering of its common shares. The Company expects to use net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
Transition Therapeutics Up 43.1% Since SmarTrend Uptrend Call (TTHI)
Comtex SmarTrend(R) - Tue Apr 21, 9:49AM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 11 months, Transition Therapeutics has returned 43.09% as of today's recent price of $7.92.
TTHI: 8.08 (+0.08)
BUYINS.NET: SMCI, PPO, TTHI, HCKT, NEPT, HST Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Apr 15, 6:24AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Super Micro Computer Inc (NASDAQ:SMCI), Polypore International Inc (NYSE
PO), TRANSITION THERAPEUTICS INC (NASDAQ:TTHI), HACKETT GROUP INCORPORATION.(THE) (NASDAQ:HCKT), Neptun SA (NASDAQ:NEPT), Host Hotels and Resorts Inc (NYSE:HST) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: HST: 20.62 (+0.07), SMCI: 31.90 (-2.91), PPO: 58.63 (+0.12), TTHI: 8.08 (+0.08), NEPT: 1.77 (-0.01), HCKT: 9.96 (+0.02)
Transition Therapeutics Has Returned 27.4% Since SmarTrend Recommendation (TTHI)
Comtex SmarTrend(R) - Tue Apr 14, 9:23AM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 10 months, Transition Therapeutics has returned 27.37% as of today's recent price of $7.05.
TTHI: 8.08 (+0.08)
Shares of TTHI Up 23.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 06, 5:26PM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 10 months, Transition Therapeutics has returned 23.39% as of today's recent price of $6.83.
TTHI: 8.08 (+0.08)
Transition Therapeutics Announces Results from Phase 1 AME & Renal Clearance Clinical Studies of Neuropsychiatric Drug Candidate ELND005
PR Newswire - Thu Mar 26, 5:01AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX:TTH) today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME" study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration ("FDA" for the approval of most drugs in development. TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
Uptrend Call Working As Transition Therapeutics Stock Rises 27.2% (TTHI)
Comtex SmarTrend(R) - Fri Mar 20, 5:00PM CDT
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 9 months, Transition Therapeutics has returned 27.19% as of today's recent price of $7.04.
TTHI: 8.08 (+0.08)
Transition Therapeutics Announces Enrolment Completion of ELND005 Phase 2 Clinical Study in Agitation and Aggression in Patients with Alzheimer's Disease
PR Newswire - Mon Mar 02, 5:02AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited ("TTIL" completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD". TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
Transition Therapeutics concludes public offering of common stock
M2 - Thu Feb 19, 4:04AM CST
Biopharmaceutical company Transition Therapeutics (NASDAQ:TTHI)(TSX:TTH) disclosed on Wednesday the completion of its public offering of 3,538,461 common shares at USD6.50 per share.
TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
Transition Therapeutics Inc. Announces Closing of Public Offering of US$23 Million of Common Shares
PR Newswire - Wed Feb 18, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) today announced the closing of its underwritten public offering of an aggregate of 3,538,461 common shares at a price to the public of US$6.50 per share, including 461,538 common shares issued upon the exercise of the underwriters' over-allotment option. Cowen and Company, LLC was the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC were the co-managers for the offering. TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
22.3% Return Seen to Date on SmarTrend Transition Therapeutics Call (TTHI)
Comtex SmarTrend(R) - Thu Feb 12, 11:04AM CST
SmarTrend identified an Uptrend for Transition Therapeutics (NASDAQ:TTHI) on June 10th, 2014 at $5.54. In approximately 8 months, Transition Therapeutics has returned 22.31% as of today's recent price of $6.77.
TTHI: 8.08 (+0.08)
Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares
PR Newswire - Thu Feb 12, 7:00AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) today announced the pricing of its underwritten public offering of 3,076,923 common shares at a price to the public of US$6.50 per share for total gross proceeds of US$20 million. The Company has granted the underwriters a 30-day option to purchase up to an additional 461,538 common shares, which could result in an additional US$3 million of gross proceeds. The offering is expected to close on February 18, 2015, subject to customary closing conditions. Cowen and Company, LLC is the sole book-running manager and Canaccord Genuity Inc., H.C. Wainwright & Co., LLC, and LifeSci Capital LLC are the co-managers for the offering. TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
Transition Therapeutics initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 3:20PM CST
TTHI: 8.08 (+0.08)
Transition Therapeutics Inc. Announces Public Offering of Common Shares
PR Newswire - Wed Feb 11, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) announced today that it has commenced an underwritten public offering of its common shares. The Company expects to use net proceeds from the sale of the common shares for general corporate purposes, including expenditures related to the advancement of the Company's drug candidates through the various clinical trial phases. TTH.TO: 10.00 (+0.11), TTHI: 8.08 (+0.08)
